# Integer Holdings Corp: Form 10-Q for the period ended Oct 1, 2010

- Company: [Integer Holdings Corp](/companies/itgr.md) (CIK 1114483)
- Form: 10-Q
- Filed: 2010-11-09
- Accepted by EDGAR: Nov 9, 2010, 15:54 ET
- Period: 2010-10-01
- Accession: 0000950123-10-102985
- Inline XBRL: no
- Main document: https://www.sec.gov/Archives/edgar/data/1114483/000095012310102985/c08128e10vq.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1114483/000095012310102985/

## Management's discussion and analysis

As filed, 48,760 characters.

### Our Business

We operate our business in two reportable segments – Greatbatch Medical and Electrochem Solutions (“Electrochem”). Greatbatch Medical designs and manufactures systems, components and devices for the cardiac rhythm management (“CRM”), neuromodulation, vascular and orthopaedics markets. Greatbatch Medical customers include large multi-national original equipment manufacturers (“OEMs”). Greatbatch Medical products include: 1) batteries, capacitors, filtered and unfiltered feedthroughs, engineered components and enclosures used in implantable medical devices (“IMDs”); 2) introducers, catheters, steerable sheaths and implantable stimulation leads; and 3) instruments and delivery systems used in reconstructive, trauma and spine surgeries as well as hip, knee and shoulder implants. Additionally, Greatbatch Medical offers value-added assembly and design engineering services for medical systems and devices within the markets in which it operates.

Electrochem provides technology solutions for critical industrial applications, including customized battery power and wireless sensing systems. Originating from the lithium cell invented for the implantable pacemaker by our Company’s founder, Wilson Greatbatch, Electrochem’s technology and superior quality and reliability is utilized in markets world-wide.

### Our Customers

Greatbatch Medical customers include leading OEMs, in alphabetical order here and throughout this report, such as Biotronik, Boston Scientific, DePuy, Johnson & Johnson, Medtronic, Smith & Nephew, Sorin Group, St. Jude Medical, Stryker and Zimmer. The nature and extent of our selling relationships with each OEM varies in terms of breadth of products purchased, purchased product volumes, length of contractual commitment, ordering patterns, inventory management and selling prices. During the nine months ended October 1, 2010, Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical collectively accounted for 60% of our total sales.

\- 25 -

The initial term of our supply agreement with Boston Scientific pursuant to which Boston Scientific purchases a certain percentage of the batteries, capacitors, filtered feedthroughs and case halves it uses in its IMDs ends on December 31, 2010. We are actively negotiating a follow-on to this agreement with expected completion during 2010 and do not expect an interruption in supply to the customer. Additionally, the new agreement may include products from our vascular systems platform.

Our Electrochem customers operate in the energy, security, portable medical and environmental monitoring markets and include 3M, Halliburton, Honeywell, Weatherford and Zoll Medical.

### Financial Overview

Third quarter 2010 sales grew 5% over the prior year to $127.5 million, reflecting improvements in our vascular, orthopaedics and Electrochem markets, which were negatively impacted in the 2009 period by customer inventory adjustments and a contraction in the underlying markets which have now begun to ease. For the first nine months of 2010, sales of $400 million were 1% higher than the prior year period as improvements in Electrochem revenue were partially offset by the slowdown in the CRM market, which caused customers to reduce inventory levels.

We prepare our financial statements in accordance with generally accepted accounting principles in the United States of America (“GAAP”). Additionally, we consistently report and discuss in our quarterly earnings releases and investor presentations adjusted operating income and margin, adjusted net income and adjusted earnings per diluted share. These adjusted amounts consist of GAAP amounts excluding the following adjustments to the extent they occur during the period: (i) acquisition-related charges; (ii) facility consolidation; manufacturing transfer and system integration charges; (iii) asset write-down and disposition charges; (iv) litigation charges; (v) the non-cash impact of accounting changes, (vi) unusual or non-routine gains/charges that are not expected to reoccur and (vii) the income tax provision (benefit) related to these adjustments. We believe that reporting these amounts provides important supplemental information to our investors and creditors seeking to understand the financial and business trends relating to our financial condition and results of operations. Additionally, performance-based compensation of our executive management is determined utilizing these adjusted amounts.

GAAP operating income for the third quarter and year-to-date periods of 2010 were above the comparable prior year periods. Prior year GAAP results included a $34.5 million litigation charge related to a jury verdict against our Electrochem subsidiary as well as a higher level of consolidation and integration charges as those projects, which took place during 2009, were substantially completed by the end of that year. Selling, general and administrative expenses (“SG&A”) for the 2010 third quarter included $0.9 million in death benefits provided to the family of the Company’s former Senior Vice President — Orthopaedics. Adjusted operating income, which excludes these charges, was $14.4 million, or 11.3% of sales, in the third quarter of 2010, compared to $13.6 million, or 11.2% of sales, for the comparable 2009 period. Adjusted operating income for the first three quarters of 2010 was $47.2 million or 11.8% of sales compared to $46.1 million or 11.7% of sales for the comparable 2009 period. These increases were primarily due to higher gross profit levels, partially offset by an increase in net research, development and engineering costs (“RD&E”), which, as expected, were higher in the current year period due to further investment in the development of new technologies, including systems level projects, in order to create long-term growth opportunities. Additionally, adjusted operating income benefited in the 2010 periods from a lower level of SG&A due to our various consolidation and cost reduction initiatives that we have implemented over the last two years.

\- 26 -

A reconciliation of GAAP operating income (loss) to adjusted amounts is as follows (in thousands):

|  | Three Months Ended October 1, 2010 | October 2, 2009 | Nine Months Ended October 1, 2010 | October 2, 2009 |
| --- | ---: | ---: | ---: | ---: |
| Operating income (loss) as reported | $13,169 | $(23,933) | $44,482 | $3,335 |
| Adjustments: |  |  |  |  |
| Executive death benefits (SG&A) | 885 | — | 885 | — |
| Litigation charge | — | 34,500 | — | 34,500 |
| Consolidation costs | 224 | 1,449 | 1,080 | 4,926 |
| Integration expenses | 5 | 1,196 | 135 | 2,776 |
| Asset dispositions and other | 96 | 434 | 597 | 604 |
| Adjusted operating income | $14,379 | $13,646 | $47,179 | $46,141 |
| Adjusted operating margin | 11.3% | 11.2% | 11.8% | 11.7% |

This higher level of GAAP and adjusted operating income for the 2010 periods was offset by a higher effective tax rate than the prior year periods due to a higher level of discrete tax items during the 2009 periods and the expiration of the U.S. R&D tax credit at the end of 2009. The 2010 GAAP and adjusted effective tax rates benefitted from higher income from lower foreign tax rate jurisdictions. As a result, GAAP diluted earnings per share (“EPS”) was $0.25 per share and $0.82 per share for the third quarter and year-to-date period of 2010, respectively, compared to a loss of $0.90 per share and $0.33 per share for the comparable 2009 periods. Adjusted diluted EPS was $0.34 per share and $1.06 per share for the third quarter and year-to-date period of 2010, respectively, compared to $0.32 per share and $1.12 per share for the comparable 2009 periods.

A reconciliation of GAAP net income (loss) and diluted EPS to adjusted amounts is as follows (in thousands, except per share amounts):

|  | Three Months Ended October 1, 2010 | October 2, 2009 | Nine Months Ended October 1, 2010 | October 2, 2009 |
| --- | ---: | ---: | ---: | ---: |
| Income (loss) before taxes as reported | $8,290 | $(28,694) | $28,805 | $(10,821) |
| Adjustments: |  |  |  |  |
| Executive death benefits (SG&A) | 885 | — | 885 | — |
| Litigation charge | — | 34,500 | — | 34,500 |
| Consolidation costs | 224 | 1,449 | 1,080 | 4,926 |
| Integration expenses | 5 | 1,196 | 135 | 2,776 |
| Asset dispositions and other | 96 | 434 | 597 | 604 |
| CSN II conversion option discount amortization | 1,987 | 1,844 | 5,852 | 5,432 |
| Adjusted income before taxes | 11,487 | 10,729 | 37,354 | 37,417 |
| Adjusted provision for income taxes | 3,445 | 3,237 | 12,498 | 10,968 |
| Adjusted net income | $8,042 | $7,492 | $24,856 | $26,449 |
| Adjusted diluted EPS | $0.34 | $0.32 | $1.06 | $1.12 |
| Number of shares | 23,406 | 23,886 | 23,788 | 23,911 |

\- 27 -

Cash flows from operations for the third quarter of 2010 were $28 million and helped fund the repayment of $27 million on our outstanding line of credit. For the year, we have generated $72 million of cash flow from operations and repaid $57 million of debt. We currently expect that cash flow from operations will continue to be used to support routine capital expenditures, further pay down debt and fund our research and development projects.

### Our CEO’s View

Given the challenging market dynamics, we are pleased with our third quarter financial results. Similar to our peers and customers, we began to see the impact of a slow-down in the cardiac rhythm management market during the third quarter. More broadly speaking, growth rates for all of our medical markets are below what was originally anticipated at the beginning of the year, and these difficult market conditions are expected to persist for the foreseeable future. That said, as a result of our diversification strategy, we were able to increase our revenue over the prior year as our vascular, orthopaedics and Electrochem product lines continued to recover. Taking all of this into consideration, we continue to expect our 2010 sales results will be within our original guidance, albeit at the lower end of the range.

As expected, our investment in research, development and engineering increased over the prior year, which was partially funded by a reduced level of adjusted selling, general and administrative costs. As we progress through the remainder of the year, we are mindful of the challenging industry environment and will continue to tightly manage our operating expenses. However, we also intend to continue to invest in our long-term future by developing innovative solutions for our customers. This includes furthering the progress already made in the development of systems and device level projects, which will drive future growth and long-term shareholder value.

### Government Regulation

In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act (collectively “Health Care Reform”) legislating broad-based changes to the U.S. health care system. Health Care Reform could significantly impact our business operations and financial results, including higher or lower revenue, as well as higher employee medical costs and taxes. Many significant parts of the legislation will be phased in over the next eight years and require further guidance and clarification in the form of regulations. As a result, many of the impacts of Health Care Reform will not be known until those regulations are enacted, which we expect to occur over the next several years.

On January 11, 2010, the U.S. Department of Transportation, and the Pipeline and Hazardous Materials Safety Administration (“PHMSA”) issued a Notice of Proposed Rulemaking, “Hazardous Materials: Transportation of Lithium Batteries” in the federal register. PMHSA, in conjunction with the Federal Aviation Administration is proposing to amend requirements in the hazardous materials regulations on the transportation of lithium cells and batteries, including lithium cell and batteries packed with or contained in equipment. The Company is actively monitoring this rulemaking process because of the potential negative effect the rule, as currently proposed, could have on our Greatbatch Medical and Electrochem businesses.

### Product Development

Currently, we are developing a series of new products for customer applications in the CRM, neuromodulation, vascular, orthopaedics and Electrochem markets. Some of the key development initiatives include:

1\. To develop complete system and device solutions for our customers in the markets we operate in;

2\. To continue development of MRI compatible leadwires and other neuromodulation products;

\- 28 -

3\. To continue development of higher energy/higher density capacitors;

4\. To integrate Biomimetic coating technology with our therapy delivery devices;

5\. To complete the design of next generation steerable catheters, sheaths and introducers;

6\. To further develop minimally invasive surgical techniques for the orthopaedics industry;

7\. To develop disposable instrumentation for the orthopaedics industry;

8\. To provide wireless sensing solutions to Electrochem customers; and

9\. To develop a charging platform for Electrochem’s secondary offering.

As a result of the investments we have made over the last two years, we are now in a position to provide our customers with full “system” solutions. This includes providing comprehensive products and services, from development and regulatory submissions through manufacturing and supporting worldwide distribution. These systems are niche product solutions that complement our OEM customers’ products and utilize our expertise and capabilities. This strategy includes partnering with our OEM customers, including sharing technology and resources, in order to bring these solutions to market. The benefits to our OEM customers include shortening the time to market for these products by accelerating the velocity of innovation, optimizing their supply chain and ultimately providing them with cost efficiencies.

As previously disclosed, on March 15, 2010 Greatbatch Medical received clearance from the U.S. Food and Drug Administration for its OptiSeal™ Valved PTFE Peelable Introducer. We have also received approval in Canada and OptiSeal™ is CE marked for distribution in Europe. OptiSeal™ represents the first 510(k) regulatory clearance received under the Greatbatch Medical brand and is a result of the significant investments made over the last few years.

OptiSeal™ represents the type of niche “system” level products that we are trying to provide. That is, products that are complementary to the core products of our customers and utilize our expertise and capabilities. OptiSeal™ was developed in collaboration with our OEM customers, leverages our technology and provides our customers with value-added innovative features.

We estimate that the market opportunity for the OptiSeal™ project is approximately $10 — $20 million of annual revenue. Additionally, it provides us with an opportunity for expansion into the vascular and peripheral access markets. In the fourth quarter of 2010 we expect to finalize distribution agreements with our customers and OptiSeal™ will begin to provide a return on the R&D investment we have made over the last two years.

We expect to be able to make additional product announcements over the next several quarters after 510(k) regulatory clearance is received. The initial product announcements are expected to center around systems we are developing for the vascular market but longer-term will include our CRM, neuromodulation, orthopaedics and Electrochem markets. Ultimately our goal is to establish a cadence of system level product announcements similar to the OptiSeal™ Introducer program that will help us achieve our stated goal of growing revenue faster than the underlying markets we serve.

### Cost Savings and Consolidation Efforts

In 2010 and 2009 we recorded charges in Other Operating Expenses, Net in the Condensed Consolidated Statements of Operations related to cost savings and consolidation efforts initiated in 2007 and 2008. These initiatives were undertaken to improve our operational efficiencies and profitability. Additional information regarding the timing, cash flow and amount of future expenditures is set forth in Note 8 “Other Operating Expenses, Net” of the Notes to the Condensed Consolidated Financial Statements contained in this report.

\- 29 -

### Our Financial Results

We utilize a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31st. For 52-week years, each quarter contains 13 weeks. The third quarter of 2010 and 2009 ended on October 1, and October 2, respectively. The commentary that follows should be read in conjunction with our Condensed Consolidated Financial Statements and related notes and with the Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in our Form 10-K for the fiscal year ended January 1, 2010.

The following table presents certain selected financial information derived from our Condensed Consolidated Financial Statements for the periods presented (dollars in thousands, except per share data):

| Sales: Greatbatch Medical | Three Months Ended October 1, 2010 | October 2, 2009 | $% Change | Change | Nine Months Ended October 1, 2010 | October 2, 2009 | $% Change | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| CRM/Neuromodulation | $69,376 | $74,094 | $(4,718) | -6% | $225,139 | $229,387 | $(4,248) | -2% |
| Vascular | 9,059 | 8,375 | 684 | 8% | 28,232 | 28,260 | (28) | 0% |
| Orthopaedics | 28,046 | 23,190 | 4,856 | 21% | 87,975 | 88,662 | (687) | -1% |
| Total Greatbatch Medical | 106,481 | 105,659 | 822 | 1% | 341,346 | 346,309 | (4,963) | -1% |
| Electrochem | 21,009 | 15,811 | 5,198 | 33% | 58,968 | 49,704 | 9,264 | 19% |
| Total sales | 127,490 | 121,470 | 6,020 | 5% | 400,314 | 396,013 | 4,301 | 1% |
| Cost of sales | 85,496 | 82,333 | 3,163 | 4% | 271,197 | 271,240 | (43) | 0% |
| Gross profit | 41,994 | 39,137 | 2,857 | 7% | 129,117 | 124,773 | 4,344 | 3% |
| Gross profit as a % of sales | 32.9% | 32.2% |  |  | 32.3% | 31.5% |  |  |
| Selling, general and administrative expenses (SG&A) | 17,098 | 15,790 | 1,308 | 8% | 49,220 | 52,362 | (3,142) | -6% |
| SG&A as a % of sales | 13.4% | 13.0% |  |  | 12.3% | 13.2% |  |  |
| Research, development and engineering costs, net (RD&E) | 11,402 | 9,701 | 1,701 | 18% | 33,603 | 26,270 | 7,333 | 28% |
| RD&E as a % of sales | 8.9% | 8.0% |  |  | 8.4% | 6.6% |  |  |
| Other operating expenses, net | 325 | 37,579 | (37,254) | -99% | 1,812 | 42,806 | (40,994) | -96% |
| Operating income (loss) | 13,169 | (23,933) | 37,102 | NA | 44,482 | 3,335 | 41,147 | NA |
| Operating margin | 10.3% | -19.7% |  |  | 11.1% | 0.8% |  |  |
| Interest expense | 4,577 | 4,895 | (318) | -6% | 14,864 | 14,714 | 150 | 1% |
| Interest income | (4) | (22) | 18 | -82% | (9) | (49) | 40 | -82% |
| Other (income) expense, net | 306 | (112) | 418 | NA | 822 | (509) | 1,331 | NA |
| Provision (benefit) for income taxes | 2,326 | (8,001) | 10,327 | NA | 9,506 | (3,354) | 12,860 | NA |
| Effective tax rate | 28.1% | 27.9% |  |  | 33.0% | 31.0% |  |  |
| Net income (loss) | $5,964 | $(20,693) | $26,657 | NA | $19,299 | $(7,467) | $26,766 | NA |
| Net margin | 4.7% | -17.0% |  |  | 4.8% | -1.9% |  |  |
| Diluted earnings (loss) per share | $0.25 | $(0.90) | $1.15 | NA | $0.82 | $(0.33) | $1.15 | NA |

\- 30 -

### Sales

| Sales: Greatbatch Medical | Three Months Ended October 1, 2010 | October 2,% 2009 | Change | Nine Months Ended October 1, 2010 | October 2,% 2009 | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| CRM/Neuromodulation | $69,376 | $74,094 | -6% | $225,139 | $229,387 | -2% |
| Vascular | 9,059 | 8,375 | 8% | 28,232 | 28,260 | 0% |
| Orthopaedics | 28,046 | 23,190 | 21% | 87,975 | 88,662 | -1% |
| Total Greatbatch Medical | 106,481 | 105,659 | 1% | 341,346 | 346,309 | -1% |
| Electrochem | 21,009 | 15,811 | 33% | 58,968 | 49,704 | 19% |
| Total sales | $127,490 | $121,470 | 5% | $400,314 | $396,013 | 1% |

***Greatbatch Medical —*** CRM and neuromodulation sales for the third quarter of 2010 declined 6% compared to the prior year period. This decrease was primarily due to the slow-down in the underlying CRM market, which caused customers to reduce inventory levels. Additionally, CRM results were impacted by continued pricing pressure, as well as the timing of orders between the second and third quarter of 2010. We estimate that the impact of the timing of these orders increased second quarter sales and reduced third quarter sales by approximately $2 million. For the year, our CRM and neuromodulation revenue is down slightly from the prior year as the benefit of further adoption of the Company’s Q series batteries as well as higher capacitor and assembly revenue, were offset by lower feedthrough sales, as the 2009 period included the benefit of customer product launches.

Our visibility to customer ordering patterns is over a relatively short period of time. Our customers have inventory management programs, alternative supply arrangements, vertical integration plans and the relative market share among the OEM manufacturers changes continuously. Additionally, we face pricing pressures from our customers and in particular our four largest OEM customers upon which a significant portion of our sales is dependent. These pressures have increased as of late due to the downturn in the economy, and more specifically, the CRM markets. Consequently, these and other factors significantly impact our sales and will continue to significantly impact our sales in the future. As we move into 2011, we expect that these difficult market conditions will persist. However, we are working to offset the impact of these conditions with the launch of new systems and device projects, particularly within our vascular product line.

Third quarter 2010 sales for the vascular product line increased 8% to $9.1 million, compared to prior year sales of $8.4 million. This increase was primarily due to higher introducer sales as customer inventory reduction programs, which began in 2009, are now complete. For the year-to-date period, vascular sales were consistent with the prior year. We expect ordering patterns to now return to a more normalized rate.

Orthopaedic product line sales of $28.0 million for the third quarter 2010 were 21% above the $23.2 million for the comparable 2009 period. This increase was across all of our products as we continued to see a recovery in the orthopaedics market and our investments and expanded capabilities have begun to deliver new business. We delivered this strong performance despite the weaker euro exchange rate, which reduced third quarter orthopaedic sales by approximately $1.0 million compared to the prior year. This foreign currency impact began to ease towards the end of the third quarter and is not expected to materially impact revenue in the fourth quarter, assuming of course, that exchange rates remain at their current levels. In comparison to the 2010 second quarter, sales decreased 8% primarily due to seasonal facility shutdowns in our European operations. For the year-to-date period, orthopaedic sales were consistent with the prior year.

\- 31 -

***Electrochem —*** Third quarter 2010 sales for the Electrochem business segment were a record $21.0 million compared to $15.8 million in the third quarter 2009. The increase from the prior year primarily related to the continued recovery in the energy and portable medical markets and customers restocking inventory. We estimate that the impact of this inventory restocking was to increase sales in the second and third quarters of 2010 by approximately $3 million dollars in each quarter. We do not expect this inventory restocking to reoccur in the fourth quarter and have already begun to see a reduced level of orders. For the first three quarters of 2010, Electrochem revenue increased 19% to $59.0 million primarily due to the same factors discussed above.

***2010 Sales Outlook —*** At the beginning of the year, we provided our expectations for annual 2010 sales growth by each of our major product lines. These growth rates equated to consolidated annual sales in the range of approximately $532 million to $551 million for 2010. Due to slower underlying market growth for our Greatbatch Medical segment, we now expect to be at the lower end of this range. This guidance assumes that our CRM and neuromodulation revenue growth will be flat in comparison to last year and that our 2010 Electrochem revenue growth will be slightly above the 0%-5% range provided at the beginning of the year.

### Gross Profit

Changes to gross profit as a percentage of sales from the prior year were due to the following:

|  | Changes From Prior Year Three Months | Nine Months |
| --- | ---: | ---: |
| Capacity & productivity(a) | -1.1% | -0.7% |
| Selling price(b) | -1.1% | -0.9% |
| Mix Change(c) | 2.6% | 3.1% |
| Other | 0.3% | -0.7% |
| Total percentage point change to gross profit as a percentage of sales | 0.7% | 0.8% |

(a) Our gross profit percentage was negatively impacted from excess capacity costs driven by the lower volumes in comparison to the 2009 periods, which more than offset productivity gains from our consolidation and integration initiatives. In accordance with our inventory accounting policy, excess capacity costs are expensed.

(b) Our gross profit percentage was negatively impacted due to contractual volume price reductions and price concessions made to our larger OEM customers on certain product lines. We expect this pricing pressure to continue in the future.

(c) Our gross profit percentage was positively impacted from an increase in sales of higher margin products as a percentage of total sales, mainly in CRM and neuromodulation, vascular and Electrochem products.

We expect that our gross profit margin will continue around the current level for the remainder of the year. Over the long-term, we expect our gross profit margin to improve as more system and device level products are introduced, which typically earn a higher margin.

\- 32 -

### SG&A Expenses

Changes to SG&A expenses from the prior year were due to the following (in thousands):

|  | Changes From Prior Year Three Months | Nine Months |
| --- | ---: | ---: |
| Personnel costs(a) | $(838) | $(1,613) |
| Executive death benefits(a) | 885 | 885 |
| Litigation related fees and charges(b) | 1,174 | 143 |
| Allowance for doubtful accounts(c) | 90 | (1,304) |
| Information technology & consulting(d) | 177 | (879) |
| Other | (180) | (374) |
| Net increase (decrease) in SG&A | $1,308 | $(3,142) |

(a) Amounts represent the change in personnel costs from the 2009 periods and reflect our consolidation and cost control initiatives. Additionally, SG&A expenses for the third quarter of 2010 include death benefits provided to the family of the Company’s former Senior Vice President — Orthopaedics.

(b) Amounts represent the change in fees and charges incurred versus the 2009 periods in connection with the patent infringement action filed by Pressure Products and the Electrochem Litigation discussed in Note 10 “Commitments and Contingencies” of the Notes to the Condensed Consolidated Financial Statements contained in this report.

(c) Amounts primarily relate to lower losses incurred on uncollectible receivables compared to the 2009 periods, which included higher Electrochem and orthopaedics write-offs due to the economic slowdown.

(d) Amounts represent the change in information technology and consulting costs from the 2009 periods and reflect our cost control initiatives.

### RD&E Expenses, Net

Net RD&E costs are comprised of the following (in thousands):

|  | Three Months Ended October 1, 2010 | October 2, 2009 | Nine Months Ended October 1, 2010 | October 2, 2009 |
| --- | ---: | ---: | ---: | ---: |
| Research and development costs | $4,247 | $4,375 | $13,201 | $13,111 |
| Engineering costs | 8,782 | 7,075 | 25,599 | 19,854 |
| Less cost reimbursements | (1,627) | (1,749) | (5,197) | (6,695) |
| Engineering costs, net | 7,155 | 5,326 | 20,402 | 13,159 |
| Total RD&E | $11,402 | $9,701 | $33,603 | $26,270 |

As expected, net RD&E expenses for the quarter and year-to-date periods of 2010 were higher than the comparable 2009 periods due to further investment in the development of new technologies, including the development of systems and devices. Additionally, during 2010 we received a lower level of customer cost reimbursements. These cost reimbursements can vary significantly from period to period due to the timing of the achievement of milestones on development projects. Excluding these customer cost reimbursements, RD&E was 9.7% of sales for the first nine months of 2010 compared to 8.3% of sales in the comparable 2009 period. We anticipate that the higher level of RD&E investment will continue for the foreseeable future consistent with our long-term growth strategy.

\- 33 -

Our long-term growth strategy includes investing resources in new technologies, including system and device level solutions for our customers. This strategy involves partnering with our OEM customers, including sharing technology and resources, in order to bring these solutions to market. The benefit to our OEM customers include shortening their time to market by accelerating the velocity of innovation, optimizing their supply chain and ultimately providing them with cost efficiencies. The timeline for approval of our vascular market systems projects is shorter than for our other markets. As such, we anticipate making additional announcements, similar to the OptiSealTM project discussed in the Product Development section of this report, over the next several months.

### Other Operating Expenses, Net

Litigation charge — On October 1, 2009, a Louisiana jury found in favor of a former Electrochem customer on their claims made in connection with a failed business transaction dating back to 1997. As a result, we recorded a $34.5 million charge related to this litigation in the third quarter of 2009.

Other — The remaining other operating expenses, net is comprised of the following (in thousands):

|  | Three Months Ended October 1, 2010 | October 2, 2009 | Nine Months Ended October 1, 2010 | October 2, 2009 |
| --- | ---: | ---: | ---: | ---: |
| 2007 & 2008 facility shutdowns and consolidations(a) | $224 | $1,449 | $1,080 | $4,926 |
| Integration costs(b) | 5 | 1,196 | 135 | 2,776 |
| Asset dispositions and other(c) | 96 | 434 | 597 | 604 |
|  | $325 | $3,079 | $1,812 | $8,306 |

(a) In the 2010 and 2009 periods, we recorded charges related to our various cost savings and consolidation efforts initiated in 2007 and 2008. Over the long-term, we expect these initiatives to continue to positively impact operational efficiencies and profitability. During 2010, the Company recognized a $0.7 million write down related to its Electrochem facility ($0.2 million in the third quarter), as the estimated fair value less costs to sell was below the recorded book value. Additional information regarding the timing, cash flow and amount of future expenditures is discussed in Note 8 “Other Operating Expenses, Net” of the Notes to the Condensed Consolidated Financial Statements contained in this report. At this time, we have completed all of our publicly announced consolidation initiatives. However, we continually analyze our business to find ways to improve our operational efficiency and we expect to take additional steps to drive further improvements, particularly with respect to the optimization of our orthopaedics product line. This optimization plan is expected to be ongoing for the next several years and includes investments in machinery and equipment as well as facilities.

(b) During the 2010 and 2009 periods, we incurred costs related to the integration of the companies acquired in 2007 and 2008. The integration initiatives include the implementation of the Oracle ERP system, training and compliance with policies, as well as the implementation of lean manufacturing and six sigma initiatives. The expenses are primarily for consultants, relocation and travel costs that will not be required after the integrations are completed.

(c) During the 2010 and 2009 periods, we recorded write-downs in connection with various asset disposals.

In 2010, other operating expenses, net are expected to be approximately $4 to $6 million.

\- 34 -

### Interest Expense and Interest Income

Interest expense and interest income for the first three quarters of 2010 were relatively consistent with the same periods of 2009 as the benefit of paying down our long-term debt with excess cash flow from operations was offset by increased discount amortization and interest expense associated with the Electrochem Litigation appeal. See Note 10 “Commitments and Contingencies” of the Notes to Condensed Consolidated Financial Statements in this report.

### Other (Income) Expense, Net

Other (income) expense, net primarily includes the impact of foreign currency exchange rate fluctuations on transactions denominated in foreign currencies.

### Provision for Income Taxes

The effective tax rate for the three and nine months ended October 1, 2010 was 28.1% and 33.0% respectively, versus the 27.9% and 31.0%, respectively, for the comparable 2009 periods. The current period rate reflects a tax benefit from having higher income from operations outside the U.S., which are taxed at rates lower than the U.S. statutory rate of 35%. This benefit was more than offset by a lower amount of discrete tax items during the current year compared to 2009, as well as the absence of the research and development tax credit, which expired at the end of 2009. Pending legislation would retroactively reinstate the R&D tax credit to the beginning of 2010. We estimate that if this legislation, were enacted in the fourth quarter of 2010 as currently proposed, it would positively impact the full year effective tax rate by approximately 350 basis points.

We believe that it is reasonably possible that a reduction of approximately $1.0 million of the balance of unrecognized tax benefits may occur within the next twelve months as a result of the expiration of applicable statutes of limitation, which would positively impact our effective tax rate in the period of reduction.

### Liquidity and Capital Resources

*(Dollars in thousands)*

|  | As of October 1, 2010 | January 1, 2010 |
| --- | ---: | ---: |
| Cash and cash equivalents(a) | $42,996 | $37,864 |
| Working capital(a) | $150,630 | $119,926 |
| Current ratio(a) | 2.4 | 1.9 |

(a) These increases primarily relate to the cash flow generated from operations of $72.0 million for the first three quarters of 2010 partially offset by net expenditures for property, plant and equipment of $10.2 million and the $30.5 million payoff of the current portion of our long-term debt that came due during the second quarter of 2010.

***Revolving Line of Credit —*** We have a senior credit facility (the “Credit Facility”) consisting of a $235 million revolving line of credit, which can be increased to $335 million upon our request and approval by a majority of the lenders. The Credit Facility also contains a $15 million letter of credit subfacility and a $15 million swingline subfacility. In connection with the Electrochem Litigation, we were required to bond the amount of the judgment and statutory interest in order to appeal. We satisfied this requirement by posting a bond, which required collateralization. We received approval from the lenders supporting our Credit Facility to increase the letter of credit subfacility by $35 million for use only in connection with bonding the appeal of the Electrochem Litigation, of which $23 million was being utilized as of October 1, 2010. The Credit Facility is secured by our non-realty assets including cash, accounts and notes receivable, and inventories, and has an expiration date of May 22, 2012 with a one-time option to extend to April 1, 2013 at our option if no default has occurred.

\- 35 -

The Credit Facility is supported by a consortium of six banks with no bank controlling more than 26% of the facility. As of October 1, 2010, each bank supporting the Credit Facility has an S&P credit rating of at least BBB- or better, which is considered investment grade.

The Credit Facility requires us to maintain a ratio of adjusted EBITDA, as defined in the credit agreement, to interest expense of at least 3.00 to 1.00. For the twelve month period ending October 1, 2010, our ratio of adjusted EBITDA to interest expense, calculated in accordance with our credit agreement, was 9.8 to 1.00, well above the required limit. The Credit Facility also requires us to maintain a total leverage ratio, as defined in the credit agreement, of not greater than 4.50 to 1.00. As of October 1, 2010, our total leverage ratio, calculated in accordance with our credit agreement, was 2.75 to 1.00, well below the required limit. The calculation of adjusted EBITDA and leverage ratio exclude non-cash charges, as well as charges in connection with the Electrochem Litigation up to a limit of $35 million.

The Credit Facility contains customary events of default. Upon the occurrence and during the continuance of an event of default, a majority of the lenders may declare the outstanding advances and all other obligations under the Credit Facility immediately due and payable. See Note 5 “Debt” of the Notes to Condensed Consolidated Financial Statements in this report for a more detailed description of the Credit Facility.

Cash flows from operations for the third quarter of 2010 were $28 million and helped fund the repayment of $27 million on our outstanding line of credit. For the year, we have generated $72 million of cash flow from operations and repaid $57 million of debt. Based upon our current capital needs, we anticipate utilizing free cash flow (cash flow from operations less capital expenditures) to make principal payments on our long-term debt. As of October 1, 2010, we had $141 million of borrowing capacity available under the Credit Facility. This amount may vary from period to period based upon our debt and EBITDA levels, which impacts the covenant calculations. We believe that our cash flow from operations and the Credit Facility provide adequate liquidity to meet our short- and long- term funding needs.

***Operating activities —*** Cash flows from operations for the first nine months of 2010 were $72.0 million compared to $50.2 million for the comparable 2009 period. The increase from the prior year is primarily due to the timing of payments and lower consolidation and integrations costs as well as our strategic initiative to lower working capital balances (i.e. accounts receivable and inventory).

***Investing activities —*** Net cash used in investing activities for the first nine months of 2010 were $9.3 million and was primarily related to maintenance capital expenditures. Our current expectation is that capital spending for the remainder of 2010 will be in the range of $5 million to $10 million, of which approximately half is discretionary in nature. These purchases relate to routine maintenance investments to support our internal growth, as well as additional investment in our orthopaedics business in order to further drive operational efficiencies.

We anticipate that cash on hand along with cash flow from operations and availability under our revolving line of credit will be sufficient to fund these capital expenditures. Going forward, we will continue to consider strategically targeted and opportunistic acquisitions.

\- 36 -

***Financing activities —*** Net cash used in financing activities for the first nine months of 2010 were $57.8 million. During the third quarter of 2010, we repaid $27 million on our outstanding line of credit. For the year, we have repaid $57 million of debt. Going forward, we expect excess cash flow to be used to pay down amounts outstanding under our revolving line of credit.

***Capital Structure —*** As of October 1, 2010, our capital structure consisted of $197.8 million of convertible subordinated notes, $71.0 million of debt under our revolving line of credit and 23.3 million shares of common stock outstanding. Additionally, we had $43.0 million in cash and cash equivalents, which is sufficient to meet our short-term operating cash needs. If necessary, we have access to $141 million of borrowing capacity under our line of credit and are authorized to issue up to 100 million shares of common stock and 100 million shares of preferred stock. The market value of our outstanding common stock since our initial public offering has exceeded our book value; accordingly, we believe that if needed we can access public markets to raise additional capital. Our capital structure allows us to support our internal growth and provides liquidity for corporate development initiatives. We continually assess our financing facilities and capital structure to ensure liquidity and capital levels are sufficient to meet our strategic objectives. In the future, we may adjust our capital structure as funding opportunities present themselves.

### Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements within the meaning of Item 303(a)(4) of Regulation S-K.

### Contractual Obligations

The following table summarizes our significant contractual obligations at October 1, 2010:

| CONTRACTUAL OBLIGATIONS | Payments due by period Total | Remainder of 2010 | 2011 - 2012 | 2013 - 2014 | After 2014 |
| --- | ---: | ---: | ---: | ---: | ---: |
| Debt obligations(a) | $284,688 | $1,663 | $83,018 | $200,007 | $— |
| Operating lease obligations(b) | 14,730 | 765 | 3,941 | 3,609 | 6,415 |
| Purchase obligations(b) | 13,974 | 10,551 | 2,978 | 445 | — |
| Foreign currency contracts(b) | 8,250 | 2,250 | 6,000 | — | — |
| Pension obligations(c) | 11,389 | 226 | 2,157 | 2,482 | 6,524 |
|  | $333,031 | $15,455 | $98,094 | $206,543 | $12,939 |

(a) Includes the annual interest expense on our convertible subordinated notes of 2.25%, which is paid semi-annually. Amounts also include the expected interest expense on the $71.0 million outstanding on our line of credit based upon the period end weighted average interest rate of 3.1%, which includes the impact of our interest rate swaps outstanding. See Note 5 “Debt” of the Notes to Condensed Consolidated Financial Statements in this report for additional information about our debt obligations.

(b) See Note 10 “Commitments and Contingencies” of the Notes to Condensed Consolidated Financial Statements in this report for additional information about our operating lease, purchase obligations and foreign currency contracts.

(c) See Note 6 “Pension Plans” of the Notes to Condensed Consolidated Financial Statements in this report for additional information about our pension plan obligations. These amounts do not include any potential future contributions to our pension plan that may be necessary if the rate of return earned on pension plan assets is not sufficient to fund the rate of increase of our pension liability. Future cash contributions may be required. As of January 1, 2010, the most recent valuation date, our actuarially determined pension benefit obligation exceeded the plans assets by $4.0 million.

\- 37 -

This table does not reflect $1.6 million of unrecognized tax benefits as we are uncertain as to if or when such amounts may be settled. Refer to Note 9 “Income Taxes” of the Notes to Condensed Consolidated Financial Statements in this report for additional information about these unrecognized tax benefits. Additionally, the table does not include any potential payments that may be due in connection with the Electrochem Litigation (See Note 10 “Commitments and Contingencies” of the Notes to Condensed Consolidated Financial Statements contained in this report).

In an attempt to help offset the cost of rising health care expenses, beginning in 2010, we began self-funding the medical insurance coverage for all of our U.S. based employees. Our risk is being limited through the use of stop loss insurance which has deductibles in the amount of $0.2 million per covered participant and $9.9 million in the aggregate per year. The maximum benefit for aggregate losses is $1.0 million per year and $4.8 million per lifetime for specific individual losses. As of October 1, 2010, we have $2.9 million accrued related to the self-insurance of our medical plan, which is recorded as Accrued Expenses and Other Current Liabilities in the Condensed Consolidated Balance Sheet and is not included in the contractual obligations table above.

### Impact of Recently Issued Accounting Standards

In the normal course of business, we evaluate all new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), Securities and Exchange Commission (“SEC”), Emerging Issues Task Force (“EITF”), American Institute of Certified Public Accountants (“AICPA”) or other authoritative accounting body to determine the potential impact they may have on our Consolidated Financial Statements. Based upon this review, we do not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company’s Consolidated Financial Statements.

### Forward-Looking Statements

Some of the statements contained in this report and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations, which are subject to known and unknown risks, uncertainties and assumptions. They include statements relating to:

- future sales, expenses and profitability;
- the future development and expected growth of our business and the markets we operate in;
- our ability to successfully execute our business model and our business strategy;
- our ability to identify trends within the implantable medical devices, medical components, and Electrochem markets and to offer products and services that meet the changing needs of those markets;
- projected capital expenditures; and
- trends in government regulation, including the impact of Health Care Reform and recent proposed federal regulations impacting the transportation of lithium batteries.

\- 38 -

You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those suggested by these forward-looking statements. In evaluating these statements and our prospects generally, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and to others contained throughout this report. We are under no duty to update any of the forward-looking statements after the date of this report or to conform these statements to actual results.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors include the following: dependence upon a limited number of customers, product obsolescence, inability to market current or future products, pricing pressure from customers, reliance on third party suppliers for raw materials, products and subcomponents, fluctuating operating results, inability to maintain high quality standards for our products, challenges to our intellectual property rights, product liability claims, inability to successfully consummate and integrate acquisitions, unsuccessful expansion into new markets, competition, inability to obtain licenses to key technology, regulatory changes or consolidation in the healthcare industry, and other risks and uncertainties that arise from time to time as described in the Company’s Annual Report on Form 10-K and other periodic filings with the Securities and Exchange Commission.

## Market risk

As filed, 3,871 characters.

***Foreign Currency —*** We have significant foreign operations in France, Mexico and Switzerland, which expose the Company to foreign currency exchange rate fluctuations due to transactions denominated in Euros, Pesos and Swiss Francs, respectively. We continuously evaluate our foreign currency risk and will take action from time to time in order to best mitigate these risks, which includes the use of various derivative instruments such as forward currency exchange contracts. See Note 10 “Commitments and Contingencies” of the Notes to Condensed Consolidated Financial Statements in this report for additional information about our forward currency exchange contracts. A hypothetical 10% change in the value of the U.S. dollar in relation to our most significant foreign currency exposures would have had an impact of approximately $8 million on our annual sales. This amount is not indicative of the hypothetical net earnings impact due to partially offsetting impacts on cost of sales and operating expenses in those currencies.

We translate all assets and liabilities of our foreign operations, where the U.S. dollar is not the functional currency, at the period-end exchange rate and translate sales and expenses at the average exchange rates in effect during the period. The net effect of these translation adjustments is recorded in the Condensed Consolidated Financial Statements as Comprehensive Income (Loss). The cumulative translation adjustment as of October 1, 2010 was an $8.9 million gain. Translation adjustments are not adjusted for income taxes as they relate to permanent investments in our foreign subsidiaries. Net foreign currency transaction gains and losses included in Other Expense, Net amounted to a loss of $0.8 million and gain of $0.6 million for the first nine months of 2010 and 2009, respectively. A hypothetical 10% change in the value of the U.S. dollar in relation to our most significant foreign currency net assets would have had an impact of approximately $10 million on our foreign net assets as of October 1, 2010.

\- 39 -

***Interest Rate Swaps —*** As of October 1, 2010, we had $71 million outstanding on our revolving line of credit. Interest rates reset on this debt based upon the LIBOR rate, thus subjecting us to interest rate risk. We entered into two receive floating-pay fixed interest rate swaps with a total notional value of $68 million and indexed to the six-month LIBOR rate. The objective of these swaps is to hedge against potential changes in cash flows on our outstanding revolving line of credit. No credit risk was hedged. The receive variable leg of the swaps and the variable rate paid on the revolving line of credit bear the same rate of interest, excluding the credit spread, and reset and pay interest on the same dates. See Note 5 “Debt” of the Notes to Condensed Consolidated Financial Statements in this report for additional information about our interest rate swap contracts.

The estimated negative fair value of the interest rate swap contracts of $0.6 million as of October 1, 2010 represents the amount we would have to pay to terminate the contracts. No portion of the change in fair value of the interest rate swaps during the 2010 or 2009 periods was considered ineffective. The amount recorded as additional Interest Expense related to the interest rate swaps for the third quarter of 2010 and 2009 was $0.3 million and $0.4 million, respectively, and $1.5 million and $0.9 million, respectively, for the nine months ended October 1, 2010 and October 2, 2009.

A hypothetical 10% change in the LIBOR interest rate would have an impact of approximately $0.005 million on our annual interest expense relating to the $71 million of floating rate revolving line of credit debt outstanding as $3 million of that debt is not hedged by the interest rate swap agreements we have in place.

## Controls and procedures

As filed, 1,393 characters.

a. Evaluation of Disclosure Controls and Procedures.

Our management, including the principal executive officer and principal financial officer, evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) related to the recording, processing, summarization and reporting of information in our reports that we file with the SEC as of October 1, 2010. These disclosure controls and procedures have been designed to provide reasonable assurance that material information relating to us, including our subsidiaries, is made known to our management, including these officers, by other of our employees, and that this information is recorded, processed, summarized, evaluated and reported, as applicable, within the time periods specified in the SEC’s rules and forms. Based on their evaluation, as of October 1, 2010, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective.

b. Changes in Internal Control Over Financial Reporting.

There have been no changes in our internal control over financial reporting that occurred during our last fiscal quarter to which this Quarterly Report on Form 10-Q relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

\- 40 -

## Risk factors

As filed, 140 characters.

There have been no material changes from risk factors as previously disclosed in the Company’s Form 10-K for the year ended January 1, 2010.

Filed Nov 9, 2010.
Source: SEC EDGAR, the filing index for accession 0000950123-10-102985. Last ingested by Listed: Nov 11, 2026, 00:08 ET. No prices; not investment advice.
